Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period

被引：15

作者：

Zamora Rodriguez, F. J. ^{[1
]}

Benitez Vega, C. ^{[2
]}

Sanchez-Waisen Hernandez, M. R. ^{[3
]}

Guisado Macias, J. A. ^{[4
]}

Vaz Leal, F. J. ^{[5
]}

机构：

[1] Equipo Salud Mental Zafra, Badajoz, Spain

[2] Ctr Salud Zafra, Midwife, Badajoz, Spain

[3] Complejo Hosp Torrecardenas, Almeria, Spain

[4] Complejo Hosp Univ Badajoz, Dept Psiquiatria, Hosp Infanta Cristina, Badajoz, Spain

[5] Complejo Hosp Univ Badajoz, Equipo Salud Mental Valdepasillas, Fac Med, Badajoz, Spain

来源：

PHARMACOPSYCHIATRY | 2017年 / 50卷 / 01期

关键词：

schizoaffective disorder; pregnancy; paliperidone palmitate; safety; antipsychotic treatment; ANTIPSYCHOTIC USE; PREGNANCY; SAFETY;

D O I：

10.1055/s-0042-110492

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction Paliperidone palmitate treatment of schizophrenia or schizoaffective disorder is effective and well tolerated, but there is almost no data on its safety during pregnancy. Case report An analysis is made of the safety and tolerability of paliperidone palmitate treatment throughout the gestation period in a 34-year-old patient diagnosed with schizoaffective disorder. Discussion Paliperidone palmitate treatment throughout the gestation period was safe and well tolerated by both mother and foetus, there being no malformations or other perinatal complications in the newborn to date.

引用

页码：38 / 40

页数：3

共 11 条

[1]

[Anonymous], 2011, XEPL DAT SHEET

[2] Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics [J].